Real-world evidence from users of a behavioral digital therapeutic for chronic insomnia

被引:27
作者
Ritterband, Lee M. [1 ,4 ]
Thorndike, Frances P. [2 ]
Morin, Charles M. [3 ]
Gerwien, Robert [2 ]
Enman, Nicole M. [2 ]
Xiong, Ray [2 ]
Luderer, Hilary F. [2 ]
Edington, Samantha [2 ]
Braun, Stephen [2 ]
Maricich, Yuri A. [2 ]
机构
[1] Univ Virginia, Ctr Behav Hlth & Technol, Dept Psychiat & Neurobehav Sci, Sch Med, Charlottesville, VA USA
[2] Pear Therapeut Inc, Boston, MA USA
[3] Univ Laval, Dept Psychol, Quebec City, PQ, Canada
[4] Univ Virginia, Ctr Behav Hlth & Technol, Dept Psychiat & Neurobehav Sci, Sch Med, POB 801075, Charlottesville, VA 22908 USA
关键词
CBT-I; Cognitive behavioral therapy for insomnia; SHUTi; Sleep healthy using the internet; Chronic insomnia; Prescription digital therapeutic; PDT; Somryst; RANDOMIZED CONTROLLED-TRIAL; CLINICAL-PRACTICE GUIDELINE; AMERICAN ACADEMY; SEVERITY INDEX; ADULTS; METAANALYSIS; EFFICACY; INTERVENTION; ASSOCIATION; MANAGEMENT;
D O I
10.1016/j.brat.2022.104084
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Background: There have been many research trials of various digital therapeutics, but few real world evaluations of their efficacy. This type of data, however, can provide a more rounded understanding of their impact, utility, reach, and adoption. Findings presented here focus on outcome and patient engagement data of SHUTi (Sleep Health Using the Internet), a digital therapeutic delivering Cognitive Behavioral Therapy for insomnia (CBT-I), in a large real-world dataset of adults with insomnia. Methods: 7216 adults who purchased access to SHUTi between December 2015 and February 2019 are included in the analysis. The Insomnia Severity Index (ISI) was administered at the beginning of each of six treatment Cores of the intervention. Users entered sleep diaries between Cores to track changes in sleep over time and obtain tailored sleep recommendations. Number of Cores completed and sleep diaries entered indicate program usage. Results: Users showed a reduction in mean ISI scores and a corresponding increase in effect size at the start of each subsequent Core (compared to Core 1) (range: d = 0.3-1.9). Effect sizes at the last Core relative to the first were moderate-to-large for diary-derived sleep onset latency and wake after sleep onset. A reduction in number of medicated nights was also found, with those with severe insomnia showing the largest reduction from last-to first week of treatment (d = 0.3). At the last Core, 61% met criteria for meaningful treatment response (reduction of > 7 points on ISI) and 40% met criteria for remission (ISI < 8). Engagement was comparable to SHUTi research trials. Conclusion: Consistent with controlled trials, real-world data suggest that digital therapeutics can result in relatively high levels of engagement and clinically meaningful sleep improvements.
引用
收藏
页数:9
相关论文
共 50 条
[41]   Chronic Kidney Disease Testing Among At-Risk Adults in the US Remains Low: Real-World Evidence From a National Laboratory Database [J].
Alfego, David ;
Ennis, Jennifer ;
Gillespie, Barbara ;
Lewis, Mary Jane ;
Montgomery, Elizabeth ;
Ferre, Silvia ;
Vassalotti, Joseph A. ;
Letovsky, Stanley .
DIABETES CARE, 2021, 44 (09) :2025-2032
[42]   Evaluation of real-world outcomes associated with use of a prescription digital therapeutic to treat substance use disorders [J].
Xiong, Xiaorui ;
Braun, Stephen ;
Stitzer, Maxine ;
Luderer, Hilary ;
Shafai, Gigi ;
Hare, Brendan ;
Stevenson, Michael ;
Maricich, Yuri .
AMERICAN JOURNAL ON ADDICTIONS, 2023, 32 (01) :24-31
[43]   Evidence of long-term real-world reduction in healthcare resource utilization following treatment of opioid use disorder with reSET-O, a novel prescription digital therapeutic [J].
Velez, Fulton F. ;
Ruetsch, Charles ;
Maricich, Yuri .
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2021, 21 (04) :519-520
[44]   Mineralocorticoid receptor antagonist use in renal dialysis: will evidence from prospective randomized trials confirm the results from 'real-world' evidence? [J].
Rossignol, Patrick ;
Pitt, Bertram .
EUROPEAN JOURNAL OF HEART FAILURE, 2023, 25 (03) :361-363
[45]   Real-World Data from the First US Commercial Users of an Implantable Continuous Glucose Sensor [J].
Sanchez, Patricia ;
Ghosh-Dastidar, Samanwoy ;
Tweden, Katherine S. ;
Kaufman, Francine R. .
DIABETES TECHNOLOGY & THERAPEUTICS, 2019, 21 (12) :677-681
[46]   Real-World Use of Once-Weekly Semaglutide in Type 2 Diabetes: Results from SemaglUtide Real-world Evidence (SURE) Germany [J].
Menzen, Markus ;
Berentzen, Tina Landsvig ;
Catarig, Andrei-Mircea ;
Pieperhoff, Sebastian ;
Simon, Joerg ;
Jacob, Stephan .
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2023, 131 (04) :205-215
[47]   Real-world Evidence for the Antianginal Efficacy of Trimetazidine from the Russian Observational CHOICE-2 Study [J].
Glezer, Maria .
ADVANCES IN THERAPY, 2017, 34 (04) :915-924
[48]   Metabolic syndrome and depression: evidence from a cross-sectional study of real-world data in Japan [J].
Sugimoto, Kumi ;
Yamada, Takuya ;
Kitazawa, Atsushi ;
Fukuda, Yoshiharu .
ENVIRONMENTAL HEALTH AND PREVENTIVE MEDICINE, 2024, 29
[49]   Comparative effectiveness of antidepressants on geriatric depression: Real-world evidence from a population-based study [J].
Hsu, Chih-Wei ;
Tseng, Wei-Ting ;
Wang, Liang-Jen ;
Yang, Yao-Hsu ;
Kao, Hung-Yu ;
Lin, Pao-Yen .
JOURNAL OF AFFECTIVE DISORDERS, 2022, 296 :609-615
[50]   Weight changes following antidiabetic mediation use: Real-world evidence from health system data [J].
Lyu, Beini ;
Grams, Morgan E. ;
Inker, Lesley A. ;
Chang, Alex R. ;
Selvin, Elizabeth ;
Shin, Jung-Im .
OBESITY SCIENCE & PRACTICE, 2022, 8 (05) :657-669